220 related articles for article (PubMed ID: 24358948)
1. Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?
Zajdel P; Partyka A; Marciniec K; Bojarski AJ; Pawlowski M; Wesolowska A
Future Med Chem; 2014 Jan; 6(1):57-75. PubMed ID: 24358948
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.
Zajdel P; Marciniec K; Maślankiewicz A; Grychowska K; Satała G; Duszyńska B; Lenda T; Siwek A; Nowak G; Partyka A; Wróbel D; Jastrzębska-Więsek M; Bojarski AJ; Wesołowska A; Pawłowski M
Eur J Med Chem; 2013 Feb; 60():42-50. PubMed ID: 23279866
[TBL] [Abstract][Full Text] [Related]
3. Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation.
Zajdel P; Marciniec K; Maślankiewicz A; Satała G; Duszyńska B; Bojarski AJ; Partyka A; Jastrzębska-Więsek M; Wróbel D; Wesołowska A; Pawłowski M
Bioorg Med Chem; 2012 Feb; 20(4):1545-56. PubMed ID: 22277589
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole: a review of its pharmacology and clinical use.
Taylor DM
Int J Clin Pract; 2003; 57(1):49-54. PubMed ID: 12587943
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.
Davies MA; Sheffler DJ; Roth BL
CNS Drug Rev; 2004; 10(4):317-36. PubMed ID: 15592581
[TBL] [Abstract][Full Text] [Related]
7. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.
Newman-Tancredi A; Cussac D; Depoortere R
Curr Opin Investig Drugs; 2007 Jul; 8(7):539-54. PubMed ID: 17659474
[TBL] [Abstract][Full Text] [Related]
8. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
9. Aripiprazole in the treatment of Alzheimer's disease.
De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.
Tsai SJ
Med Hypotheses; 2004; 63(6):1047-50. PubMed ID: 15504573
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kikuchi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
[TBL] [Abstract][Full Text] [Related]
13. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
Thomas P
Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole (Otsuka Pharmaceutical Co).
Ozdemir V; Fourie J; Ozdener F
Curr Opin Investig Drugs; 2002 Jan; 3(1):113-20. PubMed ID: 12054061
[TBL] [Abstract][Full Text] [Related]
16. (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist.
TenBrink RE; Bergh CL; Duncan JN; Harris DW; Huff RM; Lahti RA; Lawson CF; Lutzke BS; Martin IJ; Rees SA; Schlachter SK; Sih JC; Smith MW
J Med Chem; 1996 Jun; 39(13):2435-7. PubMed ID: 8691438
[No Abstract] [Full Text] [Related]
17. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
Costentin J
Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
[TBL] [Abstract][Full Text] [Related]
18. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
19. [Aripiprazole: a new atypical antipsychotic drug].
Fischer B; Davids E; Gastpar M
Fortschr Neurol Psychiatr; 2004 Sep; 72(9):497-502. PubMed ID: 15365912
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole in schizophrenia: consensus guidelines.
Travis MJ; Burns T; Dursun S; Fahy T; Frangou S; Gray R; Haddad PM; Hunter R; Taylor DM; Young AH
Int J Clin Pract; 2005 Apr; 59(4):485-95. PubMed ID: 15853869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
